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Abstract
Purpose This phase 1 study assessed the safety, tolerabil-
ity, pharmacokinetics, and preliminary antitumor activity of
linifanib in Japanese patients with advanced solid tumors.
Methods Patients were assigned to one of four sequential
cohorts (0.05, 0.10, 0.20, or 0.25 mg/kg) of oral, once-daily
linifanib on a 21-day cycle. Adverse events (AEs) were
assessed per common terminology criteria for adverse
events v3.0; tumor responses were assessed by response
evaluation criteria in solid tumors.
Results Eighteen patients were enrolled. Eleven (61%)
received C3 prior therapies. Dose-limiting toxicities were
Grade 3 ALT increase (0.10 mg/kg linifanib) and Grade 1
T-wave inversion (0.25 mg/kg linifanib) requiring dose
interruption for [7 days and discontinuation on day 29.
The most common linifanib-related AE was hypertension.
Other signiﬁcant treatment-related AEs included protein-
uria, fatigue, and palmar-plantar erythrodysaesthesia.
Linifanib pharmacokinetics were dose-proportional across
0.10–0.25 mg/kg. Two patients (11.1%) had conﬁrmed
partial responses, 12 had a best response of stable disease
(11 had stable disease for C12 weeks), and four patients
were not evaluable due to incomplete data. Four patients
(lung cancer, breast cancer, thymic cancer, sarcoma) have
continued linifanib for C48 weeks (range, 48–96? weeks).
Conclusion Linifanib was well tolerated with promising
preliminary clinical activity in Japanese patients. Later-
phase global studies examining linifanib efﬁcacy will
include Japanese patients.
Keywords Angiogenesis  Linifanib (ABT-869) 
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Introduction
Angiogenesis is a complex process of vascular network
formationessentialforgrowthandmetastasisofbothnormal
and tumor cells, supported by vascular endothelial growth
factors (VEGF) and platelet-derived growth factors (PDGF)
bindingtothereceptortyrosinekinases (RTKs)VEGFRand
PDGFR [1–4]. Excessive production of VEGF, PDGF, and
placentalgrowthfactor(PlGF)bysolidtumorcellscanresult
in excessive angiogenesis [5], and dysregulation of growth-
factor/RTK interactions on tumors and tumor vasculature
can result in increased tumor growth and metastasis [4].
Consequently, the inhibition of VEGF, PDGF, and their
RTKs is a potential target for cancer therapy [6, 7].
Small-molecule RTK inhibitors constitute the largest
category of antiangiogenic anticancer drugs. Three RTK
inhibitors, sorafenib, sunitinib, and pazopanib, target mul-
tiple receptors including VEGFR and PDGFR, and are
approved for treatment in various solid tumor types. Other
multiple RTK inhibitors in development for treatment of
solid tumors include axitinib, motesanib, vandetanib,
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DOI 10.1007/s00280-012-1846-6cediranib, brivanib, and SU14813. Combined inhibition of
VEGFR and PDGFR is hypothesized to have a greater
antitumor effect than inhibition of individual receptors [8].
Multiple-targeted RTK inhibitors, however, lack target
speciﬁcity, which can result in unexpected toxicity, includ-
ing fatigue, rash, myalgia, and hand-foot syndrome [5].
Linifanib (ABT-869) is a novel, potent inhibitor with
selectivity for the VEGFR and PDGFR family of receptor
tyrosine kinases. It has speciﬁc inhibitory activity against
VEGFR-1, VEGFR-2, PDGFRb, colony-stimulating factor
1 receptor, and fms-related tyrosine kinase 3, with minimal
activity against unrelated tyrosine and serine/threonine
kinases [9–11]. In preclinical studies with multiple human
tumor xenograft models, linifanib demonstrated potent
antiangiogenic and antitumor effects [9–13]. In a phase 1
study, single-agent linifanib demonstrated safety and
activity in Asian patients with refractory solid malignan-
cies [14]. Linifanib has also shown antitumor activity in
phase 2 studies in patients with non-small cell lung cancer
[15], hepatocellular carcinoma, or renal cell carcinoma
(preliminary results) [16, 17].
This phase 1 study evaluated the pharmacokinetics,
safety, and tolerability of linifanib in Japanese patients
with solid tumors, at doses similar to those in the phase 1
study in Asian patients [14], and conducted a preliminary
assessment of antitumor activity.
Patients and methods
Patients
Eligible patients were aged 20–75 years, with a histologi-
cally or cytologically conﬁrmed solid tumor refractory to
standard therapies or for which a standard effective therapy
did not exist, Eastern Cooperative Oncology Group Per-
formance Status (ECOG PS) 0–2, and adequate renal,
hepatic, and bone marrow function (absolute neutrophil
count C1,000/lL, platelets C100,000/lL, and hemoglobin
C9.0 g/dL). Exclusion criteria included body weight
B41 kg (0.05 and 0.10 mg/kg cohort) or C63 kg (0.05 mg/
kg cohort), central nervous system metastasis, proteinuria
greater than Grade 1 per the National Cancer Institute
Common Terminology Criteria for Adverse Events version
3.0 (CTCAE v3) [18], hypertension (systolic/diastolic
blood pressure[150/[95 mmHg), left ventricular ejection
fraction \50%, and serum positivity for human immuno-
deﬁciency virus, or hepatitis B or C virus.
Study design and treatment
This phase 1, open-label, dose-escalating study [19] was
approved by the institutional review boards and ethics
committees at the National Cancer Center Hospital
(NCCH), and conducted in accordance with the Good
Clinical Practice guidelines and the Declaration of Hel-
sinki. All patients gave written informed consent before
study-related procedures.
The primary study objective was to evaluate the safety,
tolerability, and pharmacokinetics of linifanib in Japanese
patients with solid tumors. The secondary objective was to
obtain a preliminary assessment of antitumor activity. An
exploratory analysis was conducted to identify potential
biomarkers that could predict linifanib activity or serve as
surrogates for clinic endpoints in future linifanib studies.
A standard 3 ? 3 design determined the dose level
assignment. Patients were assigned to one of four sequential
dose cohorts of once-a-day dose regimen of oral linifanib:
0.05,0.10,0.20,or0.25 mg/kg,administeredinthemorning.
The 0.25 mg/kg dose was the highest dose planned in order
toestablishauniformglobalphase2dose,sinceapriorphase
1 study in non-Japanese resulted in a recommended phase 2
dose of 0.25 mg/kg [14]. Dose-limiting toxicity (DLT) was
deﬁned as Grade 4 neutropenia lasting [7 days, Grade 4
thrombocytopenia or decreased hemoglobin, Grade 3 or
greater thrombocytopenia (if blood transfusion was
required), febrile neutropenia, non-hematological toxicity
exceptformanageablenausea,vomiting,anorexia,diarrhea,
constipation or electrolyte abnormality, or a toxicity that
required suspension of study drug for[7 days.
Patients self-administered linifanib once daily, on a
21-day cycle after fasting, and treatment continued until
disease progression or intolerable toxicity. Patients were
discontinued from study participation if they exhibited
disease progression, had linifanib-related toxicities requir-
ing [2 weeks of dose interruption, or required alternate
antineoplastic therapy. The initial oral dose, 2.5–25.0 mg
in increments of 2.5 mg, was determined by the patients’
weights. At each dose reduction, the linifanib dose was
generally decreased by 2.5 mg. The dose was reduced by
5.0 mg for patients C86 kg in the 0.10 mg/kg cohort, for
patients in the 0.20 mg/kg cohort who were C81 kg at the
ﬁrst reduction and 61–80 and C96 kg at the 2nd reduction,
and for patients in the 0.25 mg/kg cohort who were C66 kg
at the ﬁrst reduction and C86 kg at the second reduction.
Patients were discontinued if they required dose reduction,
speciﬁed by cohort: Any reduction (0.05 mg/kg cohort);
[1 reduction (0.10 mg/kg cohort, and patients B31 kg in
the 0.20 mg/kg cohort with an initial 5 mg dose); [2
reductions (0.25 mg/kg cohort, and patients C32 kg in the
0.20 mg/kg cohort with an initial C7.5 mg dose).
Tumor response and safety
Baseline evaluations included physical examination, body
weight, vital signs, 12-lead electrocardiogram, ECOG PS
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gated acquisition scan/echocardiogram. Tumor response
and/or disease progression was assessed by computerized
tomography (CT) scan or magnetic resonance imaging
(MRI) per RECIST [20] at screening and on Day (D) 1 of
every second cycle prior to the subsequent treatment period,
until tumor progression or until ﬁnal visit. Complete
response and partial response (PR) were deﬁned according
to RECIST [20]; objective response rate (ORR) was deﬁned
as the proportion of patients with best response of PR or CR
among the study population. Safety assessments included
laboratory test results and adverse events (AEs), which were
graded according to CTCAE v3 [18] and coded by medical
dictionary of regulatory activities (MedDRA) 1.0.
Pharmacokinetic and pharmacodynamic assessments
Pharmacokineticsamplingoccurredpre-doseand0.5,1,2,3,
4,6,8,and24 haftersingle-doselinifanibonCycle(C)1D1,
andpre-doseand0.5,1,2,3,4,6,and8 haftermultipleonce-
dailydoses on C1D15. Urine wascollected for24-hafter the
C1D15 dose. Linifanib and its metabolite concentrations in
plasma and urine were determined using a validated method
based on triple quadruple tandem mass spectrometry with a
lower limit of quantiﬁcation of 1.0 ng/mL.
Pharmacokinetic parameter (deﬁned in Table 3) con-
centrations were determined by non-compartmental anal-
ysis using WinNonlin Professional v.5.2 (Pharsight Corp.,
Cary, NC). Dose proportionality was evaluated by linear
regression analysis for dose-normalized (DN) maximum
observed plasma concentration (Cmax) and DN area under
the plasma concentration–time curve 0–24 h (AUC24)o n
C1D1, and DN Cmax and DN AUC24 on C1D15 across
doses 0.05, 0.1, 0.2, and 0.25 mg/kg. Additional samples
were collected at C3D1 (pre-dose) and every second cycle
until study completion or until C15D1. Concentrations for
samples at C3D1 and subsequent samples, and data from
C1D1 to C1D15 were included in the nonlinear mixed
effects models to explore covariates such as age, body
weight, and gender (data not shown). Following single-
dose linifanib at 0.25 mg/kg, a post hoc analysis compared
the pharmacokinetics between the Japanese patients in the
current study and non-Japanese patients in two phase 1
studies: Caucasian patients receiving 0.25 mg linifanib
(Abbott, unpublished) and the non-Japanese segment of
Asian patients receiving 0.10–0.30 mg/kg linifanib [14].
Plasma for biomarker analysis was collected before li-
nifanib administration on C1D1, C1D15, C2D1, and at the
ﬁnal visit. Concentration of PlGF was determined using
Abbott Architect
 kits. The relationship of PlGF levels to
outcomes was assessed post hoc. To assess the relationship
between PlGF induction and toxicity, patients were
grouped into those requiring and not requiring dose
interruption during the ﬁrst 30 days of therapy. Median
PlGF increase from baseline to C1D15 was compared as a
function of toxicity group. To assess the relationship
between PlGF induction and efﬁcacy, patients were seg-
regated into those with progressive disease (PD; N = 6) or
stable disease (SD; N = 10) at C6, and PlGF increase from
baseline to C1D15 was compared.
Statistical analysis
Continuous variables from clinical data were summarized
by the number of observations, mean, standard deviation,
median, minimum, and maximum. Discrete variables were
summarized by frequency and proportion. Statistical sig-
niﬁcance for clinical and pharmacodynamic analyses was
determined by a 2-sided P value\0.05.
Results
Patient characteristics
From September 2008 to September 2009, 18 patients with
various solid tumor types were enrolled at the NCCH in
Japan. Initial linifanib doses in each patient were 0.05 mg/
kg (n = 3), 0.10 mg/kg (n = 6), 0.20 mg/kg (n = 3), and
0.25 mg/kg (n = 6). Patient baseline and disease charac-
teristics were well balanced across the dose groups
(Table 1). The majority were women, had ECOG PS of 0,
and had received three or more prior systemic therapies
(Table 1). Median (range) treatment duration was 147 days
(7–672?). Median (range) dose intensity, deﬁned as the
percent of full-dose daily linifanib received from C1D1 to
treatment discontinuation, was 91% (33–100).
Safety and tolerability
The most common linifanib-related AEs were hypertension,
increased aspartate aminotransferase (AST), rash, neutro-
penia, and increased blood triglycerides (Table 2). There
were no Grade 3 linifanib-related AEs at the 0.05 mg/kg
dose, three at 0.10 mg/kg, two at 0.20 mg/kg, and four at
0.25 mg/kg. Grade 3 linifanib-related AEs included pro-
teinuria (n = 4), neutropenia (n = 2), increased alanine
aminotransferase (ALT) (n = 2), diarrhea, increased blood
magnesium, decreased lymphocyte count, and hyperten-
sion. There were no Grade 4 or 5 AEs. Two DLTs were
reported. One patient (0.10 mg/kg cohort) had a Grade 3
ALT increase, and one (0.25 mg/kg cohort) had a Grade 1
T-wave inversion requiring dose interruption for [7 days
and discontinuation on D29.
Adverse events leading to dose reductions were palmar-
plantar erythrodysaesthesia (n = 2), abdominal pain,
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and decreased platelet count. Adverse events leading to
dose interruptions in two or more patients were palmar-
plantar erythrodysaesthesia (n = 4), decreased platelet
count (n = 3), abdominal pain upper (n = 3), diarrhea
(n = 2), fatigue (n = 2), increased ALT (n = 2), and
proteinuria (n = 2). There were no dose reductions or
interruptions for hypertension, neutropenia, or leucopenia.
Of 16 patients who discontinued the study, 12 discontinued
due to PD, one due to PD and AE, two due to AEs, and one
due to an AE and withdrawal of consent.
Pharmacokinetics
Pharmacokinetic data were available for 18 and 16 patients
on C1D1 and C1D15, respectively. Table 3 shows the
pharmacokinetic parameters following linifanib single dose
or multiple daily doses. Linifanib was rapidly absorbed,
with average Tmax approximately 2 h across all dose levels.
Patients receiving the lowest dose had slightly higher DN
exposures over 24-h post-administration (DN AUC24).
Comparison of DN pharmacokinetic data across the 0.10,
0.20, and 0.25 mg/kg cohorts revealed no signiﬁcant trend
with dose level in peak serum concentration (DN Cmax)o r
DN AUC24 on C1D1 or C1D15 (P[0.05). The DN
AUC24 on C1D15 was approximately 1.5-fold of the DN
AUC24 on C1D1 for each dose level (accumulation ratio
approximately 1.5). The effective half-life of linifanib after
repeated daily dosing associated with this value is 15 h
(Table 3). Of 13 patients with available urine data,\15%
of the dose was recovered as unchanged drug and metab-
olite across doses. Post hoc analysis showed that the
pharmacokinetics for the Japanese patients following a
single dose in the current study were similar to those of
non-Japanese subjects in historical linifanib studies
(Table 4).
Efﬁcacy
Two patients had conﬁrmed PRs. One of these had breast
cancer and received treatment in the 0.20 mg/kg cohort for
147 days. The other had lung cancer and received treat-
ment in the 0.25 mg/kg cohort for 131 days. Figure 1
shows representative CT scans for these two patients. The
ORR was 2 of 18 patients, 11.1%. Twelve patients had SD.
Of these, 11 had SD for C12 weeks, including patients
with lung cancer, breast cancer, sarcoma, thymic cancer,
and colon cancer. Tumor response was not evaluable in
four patients; one had tumors that were not measurable at
baseline, one had tumors that were not measurable after
Table 1 Patient and disease characteristics
Baseline characteristics All patients
N = 18
Linifanib dose, mg/kg
0.05
n = 3
0.10
n = 6
0.20
n = 3
0.25
n = 6
Median age (range), years 52 (38–69) 62 (47–64) 50 (38–62) 61 (42–62) 53 (39–69)
Gender, n (%)
Male 6 (33.3) 0 2 (33.3) 0 4 (66.7)
Female 12 (66.7) 3 (100) 4 (66.7) 3 (100) 2 (33.3)
Median body weight, kg 56.5 47.3 56.5 58.1 64.0
ECOG PS
a, n (%)
0 10 (55.6) 1 (33.3) 4 (66.7) 3 (100) 2 (33.3)
1 8 (44.4) 2 (66.7) 2 (33.3) 0 4 (66.7)
Type of primary cancer, n (%)
Lung 8 (44.4) 1 (33.3) 3 (50.0) 0 4 (66.7)
Sarcoma 5 (27.8) 2 (66.7) 2 (33.3) 0 1 (16.7)
Breast 3 (16.7) 0 0 3 (100) 0
Others
b 2 (11.1) 0 1 (16.7) 0 1 (16.7)
Prior systemic therapies, n (%)
0–2 7 (38.9) 1 (33.3) 3 (50.0) 0 3 (50.0)
C3 11 (61.1) 2 (66.7) 3 (50.0) 3 (100) 3 (50.0)
Smoker, n (%)
Current or ever 6 (33.3) 0 3 (50.0) 0 3 (50.0)
ECOG PS Eastern Cooperative Oncology Group performance status
a No patients had ECOG PS C2
b Other types of primary cancers included thymic cancer (n = 1, 0.10 mg/kg) and colon cancer (n = 1, 0.25 mg/kg)
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clinical deterioration. Median (range) progression-free
survival (PFS) was 5.7 months (2.8–9.8). Median (range)
duration of response was 3.2 months (2.8–3.5). The best
tumor response at imaging assessments for each patient is
illustrated in Fig. 2. A reduction in summed tumor
dimensions of C5% was seen in 12 of the 18 patients on
study and in cohorts 0.10, 0.20, and 0.25 mg/kg.
Four patients continued linifanib with clinical beneﬁt for
C48 weeks (range, 48–96? weeks). These patients had
sarcoma, breast cancer, lung cancer, and thymic cancer. All
had a best tumor response of SD. A post hoc analysis
showed that pharmacokinetic parameter values and PlGF
levels for these four patients were not notably different
from the levels for the other patients in the study (data not
shown).
Pharmacodynamics
Induction of PlGF was observed on C1D15 and C2D1 upon
treatment with linifanib at a dose-dependent fashion.
Concentration of PlGF returned to near baseline levels at
the ﬁnal visit when patients were no longer on therapy,
indicating PlGF increase is reversible (Fig. 3a).
To explore relationships between PlGF induction and
toxicity, PlGF changes from baseline to C1D15 were
compared in patients who required a dose interruption
during the ﬁrst 30 days of therapy and those who did not.
The median (±SD) increase from baseline to C1D15 PlGF
was 22.8 pg/mL (±16.2) for the ﬁve patients who did not
need a dose interruption and was 79.9 (±55.0) for the 11
patients who did (Fig. 3b). Taken together, these data
indicate PlGF induction is dose-dependent. To examine a
Table 2 Linifanib-related adverse events by dose and grade level
Linifanib doses, mg/kg All patients
N = 18 (%)
0.05
n = 3
0.10
n = 6
0.20
n = 3
0.25
n = 6
G1 G2 G3 G1 G2 G3 G1 G2 G3 G1 G2 G3 Any grade
Linifanib-related AEs in C40% of patients
Hypertension 1 2 5 2 1 6 17 (94)
Rash 1 3 1 6 11 (61)
Proteinuria 1 2 1 1 1 2 2 10 (56)
Weight decreased 2 2 1 1 2 1 1 10 (56)
Fatigue 1 1 1 1 4 1 9 (50)
Palmar-plantar erythrodysaesthesia 3 3 3 9 (50)
Diarrhea 1 3 1 1 2 8 (44)
Hematological
Neutropenia 2 1 1 2 2 2 1 11 (61)
Leukopenia 2 1 2 3 2 10 (56)
Thrombocytopenia 1 1 2 2 2 8 (44)
Blood Chemistry
AST increased 1 4 2 6 13 (72)
Blood TG increased 1 3 1 3 2 1 11 (61)
ALT increased 1 2 1* 2 3 1 10 (56)
Blood cholesterol increased 2 3 2 1 2 10 (56)
Blood urine present 1 2 2 4 9 (50)
Blood TSH increased 3 3 1 1 8 (44)
GGT increased 3 1 1 3 8 (44)
Blood ALKP increased 1 1 1 1 4 8 (44)
Other AEs of Interest
Anorexia 1 2 1 1 2 7 (39)
T-wave abnormality 1 1
a 2 (11)
No grade 4 or 5 toxicities were observed or reported
AST aspartate aminotransferase, TG triglycerides, ALT alanine aminotransferase, TSH thyroid stimulating hormone, GGT gamma glutamyl-
transferase, ALKP alkaline phosphatase
a Dose-limiting toxicity
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were segregated into those with PD (n = 6) or SD
(n = 10) at C6. No statistically signiﬁcant difference in
PlGF change from baseline to C1D15 as a function of
response classiﬁcation (p = 0.7) was observed.
Discussion
The results of this phase 1 study showed that linifanib had a
favorable safety proﬁle in this Japanese population.
Patients had minimal DLTs (two) and no Grade 4 AEs.
Toxicities were mild to moderate and were manageable.
The most frequently observed toxicity was hypertension,
which occurred in 17 of the 18 patients across all dose
groups. All events of hypertension were Grade 1 or 2,
except for one instance of Grade 3 (0.20 mg/kg dose).
Although other phase 1 TKI studies in Japanese patient
populations have reported Grade 3 hypertension as an
adverse event [21–23], a direct comparison with the current
study is difﬁcult due to the small number of patients in the
other studies, and differences to the current study in their
dose escalation designs. In the phase 1 linifanib study in
non-Japanese Asian patients [14], Grade 3 hypertension
Table 3 Mean ± SD linifanib pharmacokinetic parameters after single (study day 1) and multiple (study day 15) doses of linifanib
Pharmacokinetic parameters, units Linifanib (mean ± SD)
0.05 mg/kg 0.10 mg/kg 0.20 mg/kg 0.25 mg/kg
Single dose
N 3636
Tmax (h) 1.65 ± 0.56 1.67 ± 0.52 1.67 ± 0.57 2.33 ± 1.03
Cmax (lg/mL) 0.09 ± 0.018 0.152 ± 0.036 0.305 ± 0.070 0.305 ± 0.068
DN Cmax (lg/mL/mg) 0.036 ± 0.007 0.026 ± 0.004 0.028 ± 0.007 0.019 ± 0.004
AUC24 (lg h/mL) 1.23 ± 0.21 1.91 ± 0.38 3.60 ± 0.43 3.78 ± 0.48
DN AUC24 (lg h/mL/mg) 0.49 ± 0.08 0.33 ± 0.04 0.33 ± 0.01 0.25 ± 0.02
Multiple dose
N 3535
Tmax (h) 2.34 ± 0.57 2.20 ± 0.45 2.33 ± 0.58 2.20 ± 0.45
Cmax (lg/mL) 0.128 ± 0.017 0.186 ± 0.064 0.390 ± 0.041 0.418 ± 0.055
DN Cmax (lg/mL/mg) 0.051 ± 0.007 0.034 ± 0.008 0.036 ± 0.003 0.028 ± 0.002
AUC24
a (lg h/mL) 1.92 ± 0.45 2.82 ± 1.03 5.63 ± 0.92 5.46 ± 1.16
DN AUC24 (lg h/mL/mg) 0.77 ± 0.18 0.50 ± 0.11 0.52 ± 0.02 0.37 ± 0.06
R
b 1.58 ± 0.34 1.46 ± 0.27 1.56 ± 0.08 1.46 ± 0.23
SD standard deviation, Tmax time to Cmax, h hour, DN dose-normalized, Cmax maximum observed plasma concentration, AUC24 area under the
concentration time curve 0–24 h
a AUC24 on C1D15 was calculated assuming the pre-dose concentration is equal to the concentration at 24 h post-dose because no 24-h
pharmacokinetic sample was drawn following the C1D15 dose
b Accumulation ratio calculated as DN AUC24 between D15 and D1
Table 4 Pharmacokinetic comparison between Japanese and non-Japanese patients with solid tumors after single doses of linifanib
Pharmacokinetic parameter Linifanib (mean ± SD)
Japanese Caucasian
a Asian
b
0.25 mg/kg 0.25 mg/kg 0.10–0.30 mg/kg
N 61 3 3 1
Tmax (h) 2.33 ± 1.03 1.77 ± 0.44 2.94 ± 1.27
DN Cmax (lg/mL/mg) 0.019 ± 0.004 0.018 ± 0.005 0.020 ± 0.008
DN AUC24 (lg h/mL/mg) 0.25 ± 0.02 0.21 ± 0.04 0.25 ± 0.10
SD standard deviation, Tmax time to Cmax, h hour, DN dose-normalized, Cmax maximum observed plasma concentration, AUC24 area under the
concentration time curve 0–24 h
a Data are from a linifanib phase 1 study [33]
b Data for these non-Japanese Asian patients (Chinese, Malay, Indian, Arab) were calculated from a linifanib phase 1 study [14]
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phase 2 dose, and in other, mixed-population, TKI phase 1
studies, including cediranib [24], motesanib [25], and
brivanib [26], Grade 3 hypertension was observed in
14–20% of patients at the phase 2 recommended dose
levels. The most common linifanib-related AEs in the
present study (hypertension, rash, neutropenia, proteinuria,
weight decreased, leukopenia, fatigue, palmar-plantar
erythrodysaesthesia) as well as linifanib-related Grade 3
AEs (proteinuria, diarrhea, neutropenia, increased ALT,
and increased blood magnesium) were comparable to the
most common drug-related AEs in other phase 1, dose-
escalating studies in multi-targeted TKIs [14, 21–32]. The
phase 1 linifanib trial in Asian patients showed that li-
nifanib-related toxicities increased in frequency and
intensity with increasing doses, hypertension was dose-
dependent, patients responded to antihypertensive therapy,
and proteinuria and skin blisters resolved after reduction or
stopping linifanib dosing. In the present study, dose
interruption or reduction was seen for Grade 2 palmar-
plantar erythrodysaesthesia and Grade 3 proteinuria; how-
ever, a relationship between the linifanib dose level and AE
incidence could not be established due to the small number
of patients in each dose group.
The 18 Japanese patients in this study received oral li-
nifanib daily at escalating doses of 0.05, 0.10, 0.20, and
0.25 mg/kg. Linifanib was rapidly absorbed with an aver-
age Tmax of approximately 2 h across all dose levels. After
15 days of repeated daily dosing, linifanib accumulated
1.5-fold and the effective half-life was approximately 15 h.
The urinary excretion of linifanib was a minor pathway
following oral administration. Similar Tmax and half-life
were seen in non-Japanese linifanib phase 1 studies [14,
33]. Daily doses C0.1 mg/kg used in the current study
achieved the efﬁcacious plasma exposures at steady state
(C2.7 lg h/mL) predicted based on a preclinical murine
HT1080 ﬁbrosarcoma model [10]. The pharmacokinetics
following single-dose administration at 0.25 mg/kg from
Fig. 1 CT images for two patients with conﬁrmed partial responses
following linifanib treatment. a A 39-year-old female patient with
lung cancer who received prior chemotherapy had lesions in the lung,
pleura, and lymph nodes. This patient had a conﬁrmed PR in C4,
following linifanib treatment at 0.25 mg/kg. Arrows indicate tumor
location at screening and at C5D1. b A 42-year-old female patient
with breast cancer who received prior chemotherapy had target
lesions in the mediastinal lymph nodes. This patient had a conﬁrmed
PR in C2, following linifanib treatment at 0.20 mg/kg. Arrows
indicate tumor location at screening and at C6D21. Abbreviations: CT
computerized tomography; PR partial response; C cycle; D day
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123this Japanese study are similar to those from the non-
Japanese phase 1 studies [14, 33]. Linifanib pharmacoki-
netics were dose-proportional over the 0.10–0.25 mg/kg
single and once-daily dose range, also reported in the li-
nifanib phase 1 dose-escalating trial in non-Japanese
patients [14].
Circulating levels of PlGF, which increase with VEGFR
inhibition, have the potential to act as a pharmacodynamic
biomarker [34]. In a previous phase 1 linifanib study, PlGF
increased dose-dependently [35]. This study conﬁrmed the
dose-dependent increase in PlGF following linifanib ther-
apy and demonstrated that larger increases in PlGF con-
centrations were observed in patients requiring a dose
reduction. In a post hoc analysis of the four patients on this
study C48 weeks, PlGF was not notably different com-
pared with the other study patients.
Conclusions regarding efﬁcacy in phase 1 studies are
necessarily limited. Although tumor evaluation was not the
primary objective of this study, linifanib demonstrated
encouraging preliminary antitumor activity across a range
of tumor types (lung cancer, breast cancer, colon cancer,
and others). Tumor reduction [5% by RECIST was
observed in the majority of patients (12/18, 67%), and PRs
were observed in two patients at the 0.20 mg/kg and
0.25 mg/kg dose levels. The four patients participating in
Fig. 2 Best percentage change from baseline in tumor size in patients treated with linifanib. Data for 17 of 18 patients are shown. Of the 18
patients in this study, one patient had no measurable lesions at baseline. This patient was not evaluable due to incomplete data
Fig. 3 Baseline subtracted day 15 placental growth factor (PlGF).
a Average PlGF increase from baseline by dose cohort. b PlGF
increase from baseline to C1D15 in patients who required a dose
interruption during the ﬁrst 30 days of therapy compared with patients
who did not. Avg average; C cycle; D day
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123the present study for C48 weeks have received 0.05 mg/
kg, 0.10 mg/kg, or 0.20 mg/kg linifanib; three had a
decrease in tumor size from baseline, and none had Grade 3
or 4 linifanib-related AEs. Substantial conclusions about
clinical efﬁcacy cannot be made due to the small size of the
population. Preliminary antitumor activity was also dem-
onstrated in a phase 1 trial of linifanib for solid tumors in
Asian patients [14] and in three phase 2 trials of linifanib
for solid tumors [15, 16, 36]. Similar, preliminary, antitu-
mor efﬁcacy has been seen in phase 1 studies of other TKIs
[21–28, 30, 32].
In summary, linifanib was well tolerated in Japanese
patients with solid tumors at the dose range 0.05–0.25 mg/kg.
Linifanib pharmacokinetics were dose-proportional at the
0.10–0.25 mg/kg dose range following single and multiple
once-daily oral administration. The pharmacokinetics of
Japanese patients following single-dose administration at
0.25 mg/kg are similar to those seen in non-Japanese
patients. Dose-dependent increases in PlGF were observed,
but did not demonstrate a clear association with patient
response to linifanib.
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